Luspatercept for Clonal Cytopenias of Uncertain Significance — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Luspatercept for Clonal Cytopenias of Uncertain Significance — Stella

Home/CCUS Clonal Cytopenia of Undetermined Significance/

View on ClinicalTrials.gov

Recruiting

Back to CCUS Clonal Cytopenia of Undetermined Significance trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Weill Cornell Medical College, New York, New York

Key details

Phase

Safety & dosing

Sponsor

Weill Medical College of Cornell University

Collaborators

Bristol-Myers Squibb

Enrollment target

~50 participants

Started

March 2025

Primary completion

February 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.